JP2001505782A5 - - Google Patents

Download PDF

Info

Publication number
JP2001505782A5
JP2001505782A5 JP1998526956A JP52695698A JP2001505782A5 JP 2001505782 A5 JP2001505782 A5 JP 2001505782A5 JP 1998526956 A JP1998526956 A JP 1998526956A JP 52695698 A JP52695698 A JP 52695698A JP 2001505782 A5 JP2001505782 A5 JP 2001505782A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998526956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001505782A (ja
JP4015201B2 (ja
Filing date
Publication date
Priority claimed from US08/982,272 external-priority patent/US7070771B1/en
Application filed filed Critical
Publication of JP2001505782A publication Critical patent/JP2001505782A/ja
Publication of JP2001505782A5 publication Critical patent/JP2001505782A5/ja
Application granted granted Critical
Publication of JP4015201B2 publication Critical patent/JP4015201B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP52695698A 1996-12-09 1997-12-08 補助分子リガンド遺伝子を含む新規な発現ベクター、ならびに免疫調節のためのならびに悪性腫瘍および自己免疫疾患の処置のためのその用途 Expired - Fee Related JP4015201B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3214596P 1996-12-09 1996-12-09
US60/032,145 1996-12-09
US08/982,272 US7070771B1 (en) 1996-12-09 1997-12-01 Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US08/982,272 1997-12-01
PCT/US1997/022740 WO1998026061A2 (en) 1996-12-09 1997-12-08 Expression vectors containing accessory molecule ligand genes and their use for immunomodulation and treatment of malignancies and autoimmune disease

Publications (3)

Publication Number Publication Date
JP2001505782A JP2001505782A (ja) 2001-05-08
JP2001505782A5 true JP2001505782A5 (https=) 2005-08-11
JP4015201B2 JP4015201B2 (ja) 2007-11-28

Family

ID=26708033

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52695698A Expired - Fee Related JP4015201B2 (ja) 1996-12-09 1997-12-08 補助分子リガンド遺伝子を含む新規な発現ベクター、ならびに免疫調節のためのならびに悪性腫瘍および自己免疫疾患の処置のためのその用途

Country Status (16)

Country Link
US (3) US7070771B1 (https=)
EP (4) EP2287309A1 (https=)
JP (1) JP4015201B2 (https=)
CN (1) CN1221662C (https=)
AT (2) ATE547524T1 (https=)
AU (1) AU5795798A (https=)
BR (1) BR9714004A (https=)
CA (2) CA2274498C (https=)
DE (1) DE69739220D1 (https=)
DK (1) DK0948614T3 (https=)
ES (1) ES2321246T3 (https=)
IL (3) IL130247A0 (https=)
NO (2) NO327411B1 (https=)
NZ (1) NZ336092A (https=)
PT (1) PT948614E (https=)
WO (1) WO1998026061A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
WO2000063395A1 (en) * 1999-04-16 2000-10-26 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
GB9917180D0 (en) * 1999-07-23 1999-09-22 Univ Sheffield Cell surface receptor
GB0025307D0 (en) * 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US20050214311A1 (en) * 2002-02-25 2005-09-29 Screaton Gavin R Novel complexes for inducing an immune response
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20080044393A1 (en) * 2004-07-16 2008-02-21 White Robert L Retinal dystrophin transgene and methods of use thereof
WO2008109825A2 (en) * 2007-03-08 2008-09-12 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
US20100050276A1 (en) * 2008-08-22 2010-02-25 Brown University Transgenic non-human animal models of apoptosis-mediated conditions
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
BR112015008612A2 (pt) * 2012-10-17 2017-09-26 Vascular Biogenics Ltd métodos de tratamento utilizando adenovirus
CN106574241A (zh) * 2014-03-27 2017-04-19 密执安大学评议会 癌症免疫疗法组合物和方法
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
CN105567679B (zh) * 2014-10-10 2019-07-05 深圳市北科生物科技有限公司 可分泌型trail蛋白构建物和表达载体
US20180244750A1 (en) 2015-11-02 2018-08-30 Memgen, Llc Methods for treatment of cancer
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
KR102660336B1 (ko) 2017-03-27 2024-04-26 내셔널 유니버시티 오브 싱가포르 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
WO2018191369A1 (en) 2017-04-12 2018-10-18 Memgen, Llc Methods of cd40 and toll like receptor immune activation
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
CN112055717B (zh) 2018-04-02 2024-04-26 新加坡国立大学 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
US12590148B2 (en) 2018-11-26 2026-03-31 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN112725379B (zh) * 2021-01-27 2024-08-13 上海南方模式生物科技股份有限公司 人源化cd40基因改造动物模型的构建方法及应用
US11585330B1 (en) * 2021-09-29 2023-02-21 Halliburton Energy Services, Inc. Flow control for geothermal well

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3750056T2 (de) 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
JPH082315B2 (ja) 1987-05-29 1996-01-17 財団法人相模中央化学研究所 リンホトキシンを含む融合蛋白質
ATE148992T1 (de) 1989-08-16 1997-03-15 Chiron Corp Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen
US5519119A (en) 1990-09-21 1996-05-21 Ishihara Sangyo Kaisha Ltd. Muteins of TNF pharmaceutical compositions and a method of making
CA2055168A1 (en) 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
AU661360B2 (en) 1991-10-25 1995-07-20 Immunex Corporation Novel cytokine
NZ251820A (en) 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
CZ283533B6 (cs) 1992-04-02 1998-04-15 F. Hoffmann-La Roche Ag TNF - muteiny a způsob jejich výroby
DE69334070T2 (de) 1992-05-26 2007-01-04 Immunex Corp., Thousand Oaks Neue zytokine die cd30 binden
AU5098493A (en) 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
EP0656947A1 (en) 1992-08-21 1995-06-14 Schering Corporation Human interleukin-13
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
US5565321A (en) 1993-01-22 1996-10-15 Immunex Corporation Detection of mutations in a CD40 ligand gene
ATE256180T1 (de) 1993-01-22 2003-12-15 Immunex Corp Detektion und behandlung von mutationen in einem gen für einen cd40-liganden
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5861310A (en) * 1993-11-03 1999-01-19 Dana-Farber Cancer Institute Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Fas抗原に結合する新規蛋白質およびそれをコードするDNA
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
EP0751781B1 (en) 1993-12-23 2004-05-26 Immunex Corporation Use of monoclonal antibodies or soluble oligomeric ligands in the manufacture of a medicament for the prevention or treatment of neoplastic disorders
JPH09508009A (ja) 1994-01-07 1997-08-19 イミュネックス・コーポレーション Fas抗原を結合するリガンド
ES2251719T3 (es) 1994-04-28 2006-05-01 Boehringer Ingelheim Pharmaceuticals Inc. Metodos para la proliferacion y diferenciacion de celulas b y su empleo.
US5606023A (en) 1994-05-24 1997-02-25 Thomas Jefferson University Mutant tumor necrosis factor proteins
US5759536A (en) 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses
JPH09508140A (ja) 1994-07-22 1997-08-19 エフ・ホフマン−ラ ロシュ アーゲー キメラtnf結合タンパク質を含有する医薬組成物
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5888764A (en) * 1995-01-20 1999-03-30 Uab Research Foundation Human fas gene promoter region
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6016832A (en) * 1997-04-16 2000-01-25 Woodward Governor Company Valve for controlling gas mass flow
CA2304130C (en) 1997-09-17 2008-10-28 Mochida Pharmaceutical Co., Ltd. Novel fas ligand derivative
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof

Similar Documents

Publication Publication Date Title
JP2000502280A5 (https=)
JP2000501599A5 (https=)
JP2000501018A5 (https=)
JP2000500076A5 (https=)
JP2000501324A5 (https=)
JP2000500055A5 (https=)
JP2000500026A5 (https=)
JP2000502472A5 (https=)
JP2000501825A5 (https=)
JP2000501338A5 (https=)
JP2000503433A5 (https=)
JP2000500874A5 (https=)
JP2000512184A5 (https=)
JP2000515132A5 (https=)
JP2000502425A5 (https=)
JP2000502568A5 (https=)
JP2000500912A5 (https=)
JP2000502570A5 (https=)
JP2001521518A5 (https=)
JP2000501229A5 (https=)
JP2000500857A5 (https=)
JP2000502316A5 (https=)
JP2001505782A5 (https=)
JP2000502714A5 (https=)
JP2000500184A5 (https=)